论文信息 - Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition

Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition

Key Points • Crystallization studies map the binding of glenzocimab to the site of dimerization in the D2 domain of GPVI.• Glenzocimab inhibits GPVI interactions with CRP, collagen, and fibrin by loss of dimerization, conformational changes, and steric hindrance.

[1] S. Watson,et al. Evidence that GPVI is Expressed as a Mixture of Monomers and Dimers, and that the D2 Domain is not Essential for GPVI Activation , 2021, Thrombosis and Haemostasis.

[2] M. Jandrot-Perrus,et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks , 2017, mAbs.

[3] K. Horii,et al. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. , 2006, Blood.

[4] J. Lacapère,et al. Identification of Residues within Human Glycoprotein VI Involved in the Binding to Collagen , 2004, Journal of Biological Chemistry.

[5] M. Jandrot-Perrus,et al. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules. , 1982, Thrombosis research.